Advances in RAB Research
Vol. 1 No. 1 (2018): Advances in Regulatory Autoantibody Research
https://doi.org/10.18416/RAB.2018.1809008

Research Article, ID Advances in RAB Research, Vol 1, No 1, 2018 • Article ID: 1809008 • DOI: 10.18416/RAB.2018.1809008

Novel targets in the diagnosis of autoimmune and non-autoimmune diseases

Main Article Content

Harald Heidecke 

Abstract

Antibodies against GPCR are present in autoimmune and non-autoimmune diseases. Furthermore, CellTrend described for the first time antibodies against growth factors (GF, e.g. VEGF-A) and their related receptors (GFR, e.g. EGF-R). Elevated as well as decreased antibodies against GPCRs, GFs and GFRs are present in many diseases. There are a growing number of antibodies against different GPCR, GF and GFRs. The following ELISAs for the quantitative determination of AT1R-Ab, ETAR-Ab, ETBR-Ab, PAR1-Ab, PAR2-Ab, M1R-Ab, M2R-Ab, M3R-Ab, M4R-Ab, M5R-Ab, Complement-Receptor-5a-Ab, CXCR3-Ab, CXCR4-Ab, ?1-adr-R-Ab, ?2-adr-R-Ab, ?1-adr-R-Ab, ?2-adr-R-Ab, VEGF-A-Ab, VEGF-B-Ab, VEGFR1-Ab, EGF-Ab, EGFR-Ab and PlGF-Ab are available as kits. Some of these assays are registered as in vitro Diagnostica (IvD). In addition, antibodies against Serotonin-R, Dopamin-R and FGF are available as a CellTrend lab service. Current findings indicate the important role of anti-GPCR, anti-GF, anti-GFR antibody patterns as markers of diseases. Therefore, further studies determining the whole spectrum of antibodies targeting GPCRs, GFs and GFRs in healthy subjects and in different diseases are necessary. New mathematic models for the analysis of the antibody patterns are required, too.

Article Details

How to Cite

Heidecke, H. (2018). Novel targets in the diagnosis of autoimmune and non-autoimmune diseases. Advances in RAB Research, 1(1), Advances in RAB Research, Vol 1, No 1, 2018 –. https://doi.org/10.18416/RAB.2018.1809008

Most read articles by the same author(s)